Tofacitinib shows promise as a treatment for Lichen Planopilaris (LPP), with significant improvement in disease activity observed in most of the 74 patients studied. However, further research is necessary to refine treatment protocols, identify predictors of response, and address gender-specific adverse effects.
79 citations
,
September 2018 in “Dermatologic therapy” Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.
1 citations
,
April 2018 in “The journal of investigative dermatology/Journal of investigative dermatology” Oral tofacitinib significantly improves lichen planopilaris symptoms without adverse effects.
9 citations
,
January 2020 in “Skin appendage disorders” Hair loss from conditions like LPP and FFA can potentially be reversed with the right treatment.
3 citations
,
February 2024 in “Journal of the American Academy of Dermatology” Topical tofacitinib cream may help treat certain hair loss conditions with fewer risks.
January 2022 in “Clinical Cases in Dermatology” A woman has a permanent hair loss condition treated with steroids and new medicines, but hair might not regrow.
